Interferon-a Receptor (phospho Ser535 / 539) Antibody

Product Specifications

Background

Interferons are widely used therapeutic agents because of their anti tumor and antiviral effects and because of their modulatory effects on the immune system. These cytokines produce their effects by binding to the Type 1 Interferon-alpha Receptor (IFNAR1) . Down regulation of this receptor plays a key role in determining the magnitude and duration of cytokine signaling. This down regulation is thought to be influenced by phosphorylation of Serine 535 and 539 in the IFNAR1.

NCBI Gene ID

3454

Swiss Prot

P17181

Accession Number

P17181

Host

Rabbit

Reactivity

Human, Mouse, Rat, Bovine

Immunogen

IFNAR1 (Ser535/539) polyclonal antibody was raised against a synthetic phosphopeptide corresponding to amino acid residues surrounding the human Phospho-Ser535, 539 Type I Interferon-a Receptor Subunit 1 (IFNAR1) .

Clonality

Polyclonal

Conjugation

Unconjugated

Type

Primary Antibodies

Field of Research

Signal Transduction, Phospho-Specific

Purification

Affinity Purified

Concentration

Batch dependent

Modification

Phospho-Specific

Shipping Conditions

Blue Ice

Storage Conditions

For long term storage –80˚ C is recommended, but shorter term storage at –20˚ C is also acceptable as aliquots may be taken without freeze/thawing due to the presence of 50% glycerol. Stable for one year.

Calculated Molecular Weight

110-130

Specificity

Interferon a Receptor antibody is specific for IFNAR1 phosphorylated at Ser535,539.

Applications Notes

Applications include Dot Blots (DB) and Western Blots (WB) . Suitability for Immunohistochemistry (IHC) has not yet been determined. When internally tested under ideal conditions the working dilutions were 1:1000 for DB and WB.

Symbol

IFNAR1

NCBI Official Name

Interferon (alpha, beta and omega) receptor 1

NCBI Organism

Homo sapiens

Background Reference 01

Suresh Kumar, K.G., Tang, W., Ravindranath, A.K., Clark, W.A., Croze, E., Fuchs, S.Y., "SCFHOS ubiquitin ligase mediates the ligand-induced down-regulation of the interferon- receptor, " The EMBO Journal, 22 (2003), 5480-5490.

Background Reference 02

Kirkwood, J., "Cancer immunotherapy: the interferon- experience, " Semin. Oncol., 29 (2002) 18-26.

Background Reference 03

Biron, C.A., "Interferons alpha and beta as immune regulators-a new look, " Immunity, 14 (2001) 661-664.

Background Reference 04

Stark, G.R., Kerr, I.M., Williams, B.R., Silverman, R.H. and Schreiber, R.D. "How cells respond to interferons." Annu. Rev. Biochem., 67 (1998) 227-264.